Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.

August 13, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex, Bandra (East), Mumbai – P.J. Towers, Dalal Street, 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 46/26-27 Our Reference No. 46/26-27 Dear Sir/ Madam, Sub: Intimation under Regulation 30 and 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Notice of the 48th Annual General Meeting and Integrated Annual Report for the Financial Year 2025-26 We wish to inform you that the 48th Annual General Meeting (“AGM”) of Glenmark Pharmaceuticals Limited (“the Company”) will be held on Friday, September 11, 2026, at 2:00 p.m. (IST) through Video Conferencing (“VC”)/ Other Audio-Visual Means (“OAVM”) in compliance with the applicable circulars issued by the Ministry of Corporate Affairs (“MCA”) and Securities and Exchange Board of India (“SEBI”). Pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended from time to time, please find enclosed Notice convening the 48th AGM and the Integrated Annual Report including BRSR for the Financial Year 2025-26. In terms of Regulation 46 of the SEBI Listing Regulations, the said Notice of 48th AGM and the Integrated Annual Report including BRSR, is also available on the website of the Company and can be accessed at https://glenmarkpharma.com/annual-report/ and on the website of National Securities Depository Limited (“NSDL”) at www.evoting.nsdl.com Further, in accordance with the applicable circular(s) issued by MCA and SEBI, the Notice of the AGM and the Integrated Annual Report of the Company, including BRSR for the Financial Year 2025-26, is being sent through electronic mode to only those Members of the Company whose e-mail addresses are registered with the Company and/ or Depository Participant(s). Further, in accordance with Regulation 36(1)(b) of the Listing Regulations, the Company will be sending a letter to Members whose e-mail addresses are not registered with Company/ DPs providing the weblink/ QR Code from where the Integrated Annual Report can be accessed on the Company’s website. Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com Information at glance: Particulars Details Mode VC / OAVM Time and date of AGM Friday, September 11, 2026 at 2.00 p.m. (IST) Participation through video conferencing https://www.evoting.nsdl.com Dividend record date Monday, August 31, 2026 Cut-off date for e-Voting Friday, September 4, 2026 Remote e-Voting start time and date Tuesday, September 8, 2026 at 9:00 AM Remote e-Voting end time and date Thursday, September 10, 2026, at 05:00 PM Remote e-Voting website of NSDL https://www.evoting.nsdl.com Results of the e-Voting On or before Tuesday, September 15, 2026 Thanking You Yours Faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Encl: As above Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com GLENMARK PHARMACEUTICALS LIMITED Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026 Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai - 400 099. Tel No: 91 22 4018 9999 Fax No: 91 22 4018 9986 CIN: L24299MH1977PLC019982 Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com NOTICE Notice is hereby given that the Forty-Eighth Annual General Meeting (“AGM”) of the Members of Glenmark Pharmaceuticals Limited (the "Company") will be held on Friday, September 11, 2026 at 2.00 p.m. (IST) through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”), to transact the following business: ORDINARY BUSINESS 1. To receive, consider, approve and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2026 together with the reports of the Board of Directors and Auditors thereon. 2. To receive, consider, approve and adopt the Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2026 together with the report of the Auditors thereon. 3. To declare dividend of INR 2.50 (Rupees Two & Fifty Paisa Only) per equity share for the Financial Year ended March 31, 2026. SPECIAL BUSINESS 4. Re-appointment of Mrs. Blanche Saldanha as a Non-Executive Director, liable to retire by rotation To consider and if thought fit, to pass the following Resolution as a Special Resolution “RESOLVED THAT pursuant to Section 152(6) of the Companies Act, 2013 and the Rules made thereunder, Mrs. Blanche Saldanha (DIN: 00007671), aged 86 years, a Non-Executive Director of the Company, who is liable to retire by rotation at this Annual General Meeting of the Company, and being eligible, has offered herself for re-appointment, be and is hereby re-appointed as a Non- Executive Director of the Company, liable to retire by rotation. RESOLVED FURTHER THAT the Board of Directors be and is hereby severally authorised to do all acts, deeds, matters and things as may be deemed necessary and/or expedient in connection therewith or incidental thereto, to give effect to the foregoing resolution.” 5. To ratify remuneration of the Cost Auditor for the financial year ending March 31, 2027 To consider and if thought fit, to pass the following resolution as an Ordinary Resolution “RESOLVED THAT pursuant to Section 148 and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), the remuneration of INR 2.8 million excluding applicable taxes and reimbursement of actual travel and out of pocket expenses, as approved by the Board of Directors of the Company to be paid to M/s. R A & Co. (Firm Registration No. 000242), the Cost Auditors of the Company for the conduct of the cost audit for the Financial Year ending March 31, 2027, be and is hereby ratified and confirmed. RESOLVED FURTHER THAT the Board of Directors (including its Committee thereof) or the Key Managerial Personnel of the Company be and is hereby severally authorised to do all acts, deeds, matters and things as may be deemed necessary and/ or expedient in connection therewith or incidental thereto, to give effect to the foregoing resolution.” By Order of the Board For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026 Place: Mumbai Date: July 31, 2026 NOTES 1. The relative Explanatory Statement, pursuant to Section 102 of the Companies Act, 2013 (‘the Act’), with respect to Item No. 4 and 5 above is annexed hereto. 2. The Ministry of Corporate Affairs (“MCA”) and Securities and Exchange Board of India (“SEBI”), have vide various circulars has dispensed with the requirement for physical attendance of the Members to the AGM. Hence, in accordance with these Circulars, the 48th AGM of the Members of the Company is being held through VC/ OAVM. The venue of the Meeting shall be deemed to be the registered office of the Company. 3. In compliance with the provisions of the Act, SEBI (Listing Obligations and Disclosure Requirements) [Showing first 8,000 characters — download PDF for full document]